Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medpace (MEDP) delivered earnings and revenue surprises of 13.33% and 3.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Surpasses Q4 Earnings and Revenue Estimates

The Stock Is Up Over 100% In 14 Months, Yet The Sentiment Is Still Bearish On Medpace Holdings

Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Medpace (MEDP) Q4 Earnings Expected to Decline

ArQule

Arrowhead Pharmaceuticals

Eidos Therapeutics Inc

Guardant Health Inc

Kodiak Sciences Inc

NeoGenomics

Nevro

Tenet Healthcare

Zoetis

Helping people stricken with illness can be richly rewarding in more ways than one.

These Were the 10 Best Healthcare Stocks of 2019

Healthcare Services Group

IQVIA Hlds

PRA Health Sciences

Syneos Health

Many investors aren’t aware of the vital roles contract research organizations fulfill for pharmaceutical and biotech companies -- or of the billions they make each year for their services.

4 Healthcare Services Companies to Own for the Future

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q3 2019 Results - Earnings Call Transcript

Medpace (MEDP) delivered earnings and revenue surprises of 0.00% and -0.24%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Q3 Earnings Meet Estimates

Lithia Motors

Mercury Systems

PennyMac Financial Services

Investment in mid-cap stocks is often recognized as a good portfolio diversification strategy during market fluctuations.

5 Must-Buy Mid-Cap Stocks Amid Global Economic Fluctuations

FTI Consulting

Fiserv

Genworth Financial

Hallmark Financial Services

Nonfarm payroll reports show jobs addition in the private sector, these are five stocks to add to your portfolio.

U.S. Private Sector Adds New Jobs: 5 Gainers

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medpace (MEDP) Soars to 52-Week High, Time to Cash Out?

DaVita

Industrial Logistics Properties

Telephone and Data Systems

Unitil

As signs of deterioration emerge, the central bank may feel compelled to cut rate for the second time in September.

5 Stocks to Buy on a Possible Second Rate Cut in September

As of late, it has definitely been a great time to be an investor in Medpace Holdings, Inc. (MEDP).

Medpace Holdings, Inc. (MEDP) Shares March Higher, Can It Continue?

New Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q2 2019 Results - Earnings Call Transcript

Medpace (MEDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Medpace (MEDP) Keep the Earnings Surprise Streak Alive?

AMN Healthcare Services

HealthEquity

Near-Term Outlook for Medical Services Industry Looks Bright

Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q1 2019 Results - Earnings Call Transcript

Tivity Health

TVTY vs. MEDP: Which Stock Is the Better Value Option?

TVTY vs. MEDP: Which Stock Should Value Investors Buy Now?

Medpace earnings of 64 cents per share on $200.7 million in sales beat first-quarter estimates on Tuesday. Medpace stock rose in early action.

This Leading Medtech Stock Just Beat First-Quarter Estimates

These winning stocks don't make many headlines but are quietly delivering strong revenue and earnings growth.

3 Under-the-Radar Healthcare Stocks With Great Growth Potential

News for Medpace Holdings Stock (MEDP)